George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah, USA.
J Biomed Mater Res B Appl Biomater. 2012 May;100(4):1163-9. doi: 10.1002/jbm.b.31979. Epub 2011 Nov 28.
One of the most practical strategies that has been undertaken to fight biofilm implant-related infections has been the development of coatings on biomaterial devices that can elute antimicrobials into regions of patients' tissues. To date, the majority of animal studies that have been developed to model infections that accompany the use of these materials have primarily involved an initial inoculum of planktonic bacterial cells from batch cultures. Although valuable, data that have been derived from these experiments may not provide important clinical insight into how bacteria in well-established, mature biofilms impact device-related and other clinical infections when they contaminate a patient site or implanted device. In this review, a discussion is presented on the impact that a shift in biofilm research may have if initial inocula of well-established, mature biofilms are used to model biomaterial device-related infections in animal models.
为了对抗与植入生物膜相关的感染，人们采取了最实用的策略之一，即在生物材料装置上开发涂层，以便将抗生素释放到患者组织区域。迄今为止，为了模拟使用这些材料时伴随发生的感染而开发的大多数动物研究主要涉及从批次培养物中初始接种浮游细菌细胞。虽然这些实验产生的数据很有价值，但它们可能无法为如何将定植于成熟生物膜中的细菌影响患者部位或植入装置污染时的设备相关和其他临床感染提供重要的临床见解。在这篇综述中，讨论了如果使用成熟的定植生物膜初始接种物来模拟动物模型中的生物材料装置相关感染，生物膜研究的转变可能会产生怎样的影响。
